Status:

RECRUITING

European Trial Into Mpox Infection

Lead Sponsor:

Miquel Ekkelenkamp

Collaborating Sponsors:

European Clinical Research Alliance for Infectious Diseases (ECRAID)

Erasmus Medical Center

Conditions:

Monkeypox

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The goal of this randomized controlled double-blind clinical trial is to test the drug tecovirimat in patients with mpox (previously known as monkeypox) disease. The main questions it aims to answer ...

Eligibility Criteria

Inclusion

  • Polymerase Chain Reaction (PCR) /Nucleic Acid Amplification Test (NAAT) -confirmed mpox infection
  • The presence of active skin or mucosal lesion(s)
  • Signed Informed Consent Form

Exclusion

  • Age \<18 years.
  • Body weight \<40 kg
  • Pregnant and breastfeeding patients are not eligible for inclusion in this study.
  • Lack of mental capacity to provide informed consent
  • Trial participation is considered not in the best interest of patient
  • Known hypersensitivity to the active substance or to any of the excipients of the study drug.
  • Use of contraindicated treatment repaglinide. (Repaglinide, an oral treatment for diabetes mellitus, may be discontinued while taking study treatment with the agreement of the patient's general practitioner, who may start alternate diabetes treatment if considered necessary.)
  • Previous, current or planned use of another investigational drug (tecovirimat) at any point during study participation.
  • The patient's own doctor considers there to be a definite indication for the patient to receive tecovirimat or the local guidelines establish that tecovirimat treatment should be initiated
  • The patient's own doctor considers there to be a definite contraindication to the patient receiving tecovirimat.
  • The patient suffers from hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

Key Trial Info

Start Date :

August 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2026

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06156566

Start Date

August 9 2024

End Date

August 1 2026

Last Update

March 28 2025

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Institute of Tropical Medicine

Antwerp, Antwerp, Belgium, 2000

2

Cliniques Universitaires St. Luc

Brussels, Belgium, 1200

3

APHP St. Louis

Paris, France, 75010

4

Universitätsklinikum Bonn

Bonn, Germany, 53127